U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H31N3O6
Molecular Weight 505.5622
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Alpha benidipine, (-)-

SMILES

COC(=O)C1=C(C)NC(C)=C([C@@H]1C2=CC=CC(=C2)[N+]([O-])=O)C(=O)O[C@@H]3CCCN(CC4=CC=CC=C4)C3

InChI

InChIKey=QZVNQOLPLYWLHQ-ZEQKJWHPSA-N
InChI=1S/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,26,29H,8,13-14,16-17H2,1-3H3/t23-,26-/m1/s1

HIDE SMILES / InChI

Molecular Formula C28H31N3O6
Molecular Weight 505.5622
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Benidipine is an orally triple L-, T-, and N-type calcium channel blocker for the treatment of hypertension and angina pectoris synthesized and developed by Kyowa Hakko Kogyo Co., Ltd. Benidipine, approved in Japan in November 1991, has become one of the three best selling CCBs and is highly useful as a potent, long-lasting antihypertensive and antianginal agent.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CONIEL

Approved Use

CONIEL is a calcium channel blocker and extensive clinical testing has demonstrated the sustained efficacy and effectiveness of this agent. A large body of evidence including clinical data and analyses demonstrates that CONIEL protects the heart, kidneys and brain from the effects of hypertension and angina pectoris.

Launch Date

1991
Primary
CONIEL

Approved Use

CONIEL is a calcium channel blocker and extensive clinical testing has demonstrated the sustained efficacy and effectiveness of this agent. A large body of evidence including clinical data and analyses demonstrates that CONIEL protects the heart, kidneys and brain from the effects of hypertension and angina pectoris.

Launch Date

1991
PubMed

PubMed

TitleDatePubMed
Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
2008-04-28
Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
2007-09
Subdepressor dose of benidipine ameliorates diabetic cardiac remodeling accompanied by normalization of upregulated endothelin system in rats.
2006-05
Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice.
2005-03-01
A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide.
2003-06
Interaction of digoxin with antihypertensive drugs via MDR1.
2002-02-15
Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
2000-05-11
[Effects of benidipine hydrochloride (Coniel) on blood pressure, heart rate and plasma norepinephrine concentration in spontaneously hypertensive rats].
1999-05
Patents

Patents

Sample Use Guides

Orally, 4 mg/day
Route of Administration: Oral
The oocytes expressing select Ca channels were cultured for 2 to 4 days and then subjected to electrophysiological measurement. The oocytes were placed in a small chamber perfused with extracellular solution , and Ba2+ currents through expressed channels were measured by the two-microelectrode voltageclamp method. The experimental chamber was 0.5 ml in volume, and it was perfused continuously with the extracellular solution. Typically, oocytes were clamped at a holding potential of 2100, 280, or 260 mV and depolarized to 110 mV for 200 ms every 15 s. Microelectrodes were filled with 3 M KCl, and those showing a resistance of 0.5 to 1.2 VM were used. Benidine was evaluated in concentration range of 0.1 - 100 uM, and demonstrated blocking effect with IC50 of 0.7 uM.
Substance Class Chemical
Created
by admin
on Wed Apr 02 19:17:01 GMT 2025
Edited
by admin
on Wed Apr 02 19:17:01 GMT 2025
Record UNII
K2TQS8L6NJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
(-)-Alpha benidipine
Preferred Name English
Alpha benidipine, (-)-
Common Name English
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-methyl 5-[(3R)-1-(phenylmethyl)-3-piperidinyl] ester, (4R)-
Systematic Name English
3-Methyl 5-[(3R)-1-(phenylmethyl)-3-piperidinyl] (4R)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
Systematic Name English
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 1-(phenylmethyl)-3-piperidinyl ester, [R-(R*,R*)]-
Systematic Name English
Code System Code Type Description
CAS
119065-60-0
Created by admin on Wed Apr 02 19:17:01 GMT 2025 , Edited by admin on Wed Apr 02 19:17:01 GMT 2025
PRIMARY
FDA UNII
K2TQS8L6NJ
Created by admin on Wed Apr 02 19:17:01 GMT 2025 , Edited by admin on Wed Apr 02 19:17:01 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT